Ralinepag

The article reviews the evolution of clinical trial endpoints for pulmonary arterial hypertension (PAH), highlighting the shift from traditional measures like 6-minute walk distance to composite endpoints such as time to clinical worsening. It discusses the challenges in validating biomarkers as surrogate endpoints and the potential of novel trial designs, including platform trials, to improve efficiency. The importance of patient-reported outcomes, diversity in trial participation, and the use of artificial intelligence in trial design are also emphasized.

Clinical trial design, end-points, and emerging therapies

Related Clinical Trials:

Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension

Dapagliflozin in Pulmonary Arterial Hypertension

Effects of DHEA in Pulmonary Hypertension

Empagliflozin in Pulmonary Arterial Hypertension

Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Positioning Imatinib for Pulmonary Arterial Hypertension

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Olaparib for PAH: a Multicenter Clinical Trial

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Effect of CS1 in Subjects With Pulmonary Arterial Hypertension

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

Spironolactone for Pulmonary Arterial Hypertension

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Drug Development Updates